A genome-wide in vivo CRISPR screen in colorectal cancer identifies DNMT3A as the top epigenetic driver.
A genome-wide in vivo CRISPR screen in colorectal cancer identifies DNMT3A as the top epigenetic driver.
It acts twice: promoter methylation silences TNFRSF1A/B, and a non-enzymatic function opens cholesterol synthesis through NFYA, producing zymosterol that blocks SREBP2 processing. The CAR-T work in this paper used the Eynos RV02-20 retroviral vector at MOI 5.
Tell us your cell type, sample source and downstream assay — we will suggest an isolation route, a culture condition and the matching catalogue numbers.